KwalitY Pharmaceuticals Limited has successfully concluded its postal ballot voting process, with shareholders overwhelmingly approving two special resolutions for the appointment of independent directors. The company announced the results on March 30, 2026, demonstrating strong shareholder confidence in the proposed board appointments.

Voting Results Overview

The postal ballot process yielded exceptional approval rates for both resolutions, with shareholders showing near-unanimous support for the company's governance initiatives.

Resolution Details and Approval

Both special resolutions received identical voting patterns, reflecting consistent shareholder sentiment across the proposed appointments.

Resolution 1: Appointment of Mr. Preetmohinder Singh Bedi

The first resolution concerned the appointment of Mr. Preetmohinder Singh Bedi (DIN: 11452004) as an Independent Director for a term of 5 consecutive years.

Resolution 2: Appointment of Mr. Bhavesh Mahajan

The second resolution approved the appointment of Mr. Bhavesh Mahajan (DIN: 09614108) as an Independent Director for a period of 5 consecutive years.

Voting Process and Timeline

The company conducted the postal ballot process through remote e-voting, ensuring accessibility for all shareholders while maintaining transparency and compliance.

Scrutinizer Appointment and Report

Rishi Mittal & Associates, Company Secretaries, served as the appointed scrutinizer for the postal ballot process. Rishi Mittal (ACS No. 12613) was appointed by the Board of Directors on February 21, 2026, and submitted the scrutinizer's report on March 29, 2026. The scrutinizer confirmed that both special resolutions were passed with the requisite majority, as the votes cast in favour exceeded three times the number of votes cast against them.

The company utilized National Securities Depository Limited (NSDL) services for the remote e-voting facility, ensuring a secure and transparent voting process for all eligible shareholders. Company Secretary Gurpreet Kaur (ACS No: 52091) served as the Compliance Officer for the process and communicated the results to the Bombay Stock Exchange under scrip code 539997.

Kwality Pharmaceuticals Limited has issued a comprehensive postal ballot notice seeking shareholder approval for the appointment of two Independent Directors through remote e-voting facility. The notice, dated February 21, 2026, outlines the company's proposal to strengthen its board governance structure with experienced professionals.

Proposed Director Appointments

The company seeks approval for two special resolutions concerning Independent Director appointments:

Dr. Preetmohinder Singh Bedi - Appointment Details

Dr. Preetmohinder Singh Bedi was initially appointed as Additional Director (Non-Executive, Independent) with effect from January 01, 2026. His proposed term as Independent Director will run from January 01, 2026 to December 31, 2030. Dr. Bedi brings extensive pharmaceutical expertise with over 28 years of experience in the field.

Professional Background:

• Professor in Department of Pharmaceutical Sciences at Guru Nanak Dev University, Amritsar
• Director, Global Ranking and International Collaboration Cell
• Included in 2025 Stanford–Elsevier list of world's top 2% scientists
• Contributed 150 publications to reputed international and national journals
• Holds patents in medicinal chemistry field

Mr. Bhavesh Mahajan - Appointment Details

Mr. Bhavesh Mahajan was appointed as Additional Director (Non-Executive, Independent) with effect from January 28, 2026. His proposed Independent Director term will span from January 28, 2026 to January 27, 2031. Mr. Mahajan contributes significant financial and audit expertise to the board.

Professional Background:

• Chartered Accountant with over 19 years of professional experience
• Senior Partner at M/s Bhavesh Mahajan & Co., Chartered Accountants
• Category-II CA firm empaneled with Reserve Bank of India since 2005
• Extensive experience in statutory audits, banking audits, and regulatory compliance

E-Voting Process and Timeline

The company has engaged National Securities Depository Limited (NSDL) to provide remote e-voting facility to shareholders. The voting process follows a structured timeline:

Regulatory Compliance and Documentation

The postal ballot notice has been issued in compliance with Section 110 of the Companies Act, 2013, and Regulation 30 of SEBI Listing Regulations. The notice is being distributed electronically to shareholders whose email addresses are registered with the company, Bigshare Services Private Limited (Registrar and Transfer Agent), or depositories as on the cut-off date.

Mr. Rishi Mittal (Membership No. A12613), Proprietor of M/s Rishi Mittal & Associates, Practicing Company Secretaries, has been appointed as Scrutinizer to oversee the remote e-voting process. The scrutinizer will ensure fair and transparent conduct of the voting process and submit the final report to the company's Chairman.

Board Recommendation and Shareholder Benefits

The Board of Directors has recommended both special resolutions for shareholder approval. The appointments are expected to enhance the company's governance framework through the appointees' diverse expertise in pharmaceutical research and financial management. Both directors will be entitled to sitting fees for board and committee meetings, aligned with fees paid to other non-executive independent directors.

The results of the postal ballot, along with the Scrutinizer's Report, will be made available on the company's website at www.kwalitypharma.com , NSDL's website, and will be communicated to BSE Limited where the company's equity shares are listed.